Niagen Bioscience, Inc.
NAGE
$10.10
$0.373.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 499.80% | 273.15% | 122.95% | 79.19% | 67.03% |
| Total Depreciation and Amortization | -12.96% | -23.17% | -25.85% | -21.31% | -16.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -139.97% | -115.29% | -30.12% | -19.63% | -3.20% |
| Change in Net Operating Assets | 406.51% | -31.30% | -161.01% | -647.99% | 172.82% |
| Cash from Operations | 326.34% | 70.14% | -32.00% | -46.31% | 190.45% |
| Capital Expenditure | -57.14% | -10.14% | 61.54% | 69.23% | 75.50% |
| Sale of Property, Plant, and Equipment | 300.00% | 300.00% | 300.00% | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -44.09% | 0.00% | 67.69% | 68.75% | 76.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 35.29% | 26.67% | 50.00% | 55.00% | -21.43% |
| Issuance of Common Stock | -- | -- | -78.82% | -92.28% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 45.35% | 30.67% | -38.71% | -11.69% | -11.69% |
| Cash from Financing | 8,340.78% | 6,065.56% | -79.84% | -93.42% | -101.35% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 534.06% | 151.82% | -58.37% | -84.15% | 105.96% |